[
  {
    "ts": null,
    "headline": "Top Analyst Reports for Visa, Merck & Southern Company",
    "summary": "Visa sees solid volume growth and cross-border gains, while Merck and Southern Company navigate competitive and regulatory pressures.",
    "url": "https://finnhub.io/api/news?id=5795d6d47387eb4d1f64c10e2e151f99b51daac8841174b6525260fac3d49f91",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763675040,
      "headline": "Top Analyst Reports for Visa, Merck & Southern Company",
      "id": 137566489,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Visa sees solid volume growth and cross-border gains, while Merck and Southern Company navigate competitive and regulatory pressures.",
      "url": "https://finnhub.io/api/news?id=5795d6d47387eb4d1f64c10e2e151f99b51daac8841174b6525260fac3d49f91"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Softer Late Afternoon",
    "summary": "Health care stocks declined late Thursday afternoon with the NYSE Health Care Index and the Health C",
    "url": "https://finnhub.io/api/news?id=4917d2d9bc9b7224b02d3ecba954d37cb32fa3fd29efcf6972f39f52d51e1e43",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763672010,
      "headline": "Sector Update: Health Care Stocks Softer Late Afternoon",
      "id": 137566589,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Health care stocks declined late Thursday afternoon with the NYSE Health Care Index and the Health C",
      "url": "https://finnhub.io/api/news?id=4917d2d9bc9b7224b02d3ecba954d37cb32fa3fd29efcf6972f39f52d51e1e43"
    }
  },
  {
    "ts": null,
    "headline": "Friday's big stock stories: What’s likely to move the market in the next trading session",
    "summary": "Stocks fell on Thursday after a volatile session that saw a more than 1,000-point reversal on the Dow and a more than 2% drop in the Nasdaq.",
    "url": "https://finnhub.io/api/news?id=337600dce2f03b0f179f3bec56be022d29802bdc46ad6f690636bbbc2ba429b0",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763666676,
      "headline": "Friday's big stock stories: What’s likely to move the market in the next trading session",
      "id": 137570196,
      "image": "https://image.cnbcfm.com/api/v1/image/108219418-1761837546035-gettyimages-2243611225-AFP_82J47WK.jpeg?v=1763668478&w=1920&h=1080",
      "related": "MRK",
      "source": "CNBC",
      "summary": "Stocks fell on Thursday after a volatile session that saw a more than 1,000-point reversal on the Dow and a more than 2% drop in the Nasdaq. ",
      "url": "https://finnhub.io/api/news?id=337600dce2f03b0f179f3bec56be022d29802bdc46ad6f690636bbbc2ba429b0"
    }
  },
  {
    "ts": null,
    "headline": "Merck's $3 Billion AI Gamble: Inside the Bold Bet to Crack Parkinson's",
    "summary": "With its pipeline under pressure, Merck turns to Valo Health's AI brainpower in a high-stakes neuroscience push",
    "url": "https://finnhub.io/api/news?id=9ca67a246d9be99117b7c5e06dd1e216827640767a18fbe2fabe4a85adcdb48c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763661819,
      "headline": "Merck's $3 Billion AI Gamble: Inside the Bold Bet to Crack Parkinson's",
      "id": 137563003,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "With its pipeline under pressure, Merck turns to Valo Health's AI brainpower in a high-stakes neuroscience push",
      "url": "https://finnhub.io/api/news?id=9ca67a246d9be99117b7c5e06dd1e216827640767a18fbe2fabe4a85adcdb48c"
    }
  },
  {
    "ts": null,
    "headline": "Merck KGaA eyes new Parkinson’s disease assets with $3bn Valo partnership",
    "summary": "Valo will use its trove of patient records and biobank samples to pinpoint potential targets for Merck’s pipeline expansion.",
    "url": "https://finnhub.io/api/news?id=2a67639e22b9cf2d58d8333edd0402ad0dd1f6d4ff6cd97e5ee9d37e0314b2e7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763657815,
      "headline": "Merck KGaA eyes new Parkinson’s disease assets with $3bn Valo partnership",
      "id": 137563004,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Valo will use its trove of patient records and biobank samples to pinpoint potential targets for Merck’s pipeline expansion.",
      "url": "https://finnhub.io/api/news?id=2a67639e22b9cf2d58d8333edd0402ad0dd1f6d4ff6cd97e5ee9d37e0314b2e7"
    }
  },
  {
    "ts": null,
    "headline": "VIPC Signs MOU with AstraZeneca, Eli Lilly, Merck to Develop the Virginia Center for Advanced Pharmaceutical Manufacturing to Train Workforce of the Future",
    "summary": "A Memorandum of Understanding (MOU) signed by the Virginia Innovation Partnership Corporation (VIPC) and AstraZeneca, Eli Lilly (Lilly), and Merck to develop the Virginia Center for Advanced Pharmaceutical Manufacturing (APM) was executed by Governor Glenn Youngkin at a statewide gathering with key leaders from Virginia's life sciences ecosystem, higher-ed universities, and community colleges on October 31. This landmark public-private industry partnership commits $120 million of workforce inves",
    "url": "https://finnhub.io/api/news?id=f5b8dd330fb63b7d7d18eb5bdce1105353fcf5a2c359fcfad59cf458e8d91ad4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763656380,
      "headline": "VIPC Signs MOU with AstraZeneca, Eli Lilly, Merck to Develop the Virginia Center for Advanced Pharmaceutical Manufacturing to Train Workforce of the Future",
      "id": 137562926,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "A Memorandum of Understanding (MOU) signed by the Virginia Innovation Partnership Corporation (VIPC) and AstraZeneca, Eli Lilly (Lilly), and Merck to develop the Virginia Center for Advanced Pharmaceutical Manufacturing (APM) was executed by Governor Glenn Youngkin at a statewide gathering with key leaders from Virginia's life sciences ecosystem, higher-ed universities, and community colleges on October 31. This landmark public-private industry partnership commits $120 million of workforce inves",
      "url": "https://finnhub.io/api/news?id=f5b8dd330fb63b7d7d18eb5bdce1105353fcf5a2c359fcfad59cf458e8d91ad4"
    }
  },
  {
    "ts": null,
    "headline": "Why Ligand Pharma, A Hidden Name Behind Two Big Drugs, Is Up 92% This Year",
    "summary": "Shares of Ligand Pharmaceuticals are absolutely flying as investors line up behind the company's unique royalty-based business model.",
    "url": "https://finnhub.io/api/news?id=641098d0e421a9de64742ccda9e754c24adaa19dcd16d05a8a0c0d548f900b00",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763656134,
      "headline": "Why Ligand Pharma, A Hidden Name Behind Two Big Drugs, Is Up 92% This Year",
      "id": 137563006,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Shares of Ligand Pharmaceuticals are absolutely flying as investors line up behind the company's unique royalty-based business model.",
      "url": "https://finnhub.io/api/news?id=641098d0e421a9de64742ccda9e754c24adaa19dcd16d05a8a0c0d548f900b00"
    }
  },
  {
    "ts": null,
    "headline": "Inside Our Portfolio: The Investments We Plan To Own For Life",
    "summary": "Building a successful portfolio relies on a concentrated, well-researched selection of high-quality compounding engines. Read more on portfolio strategy and allocation.",
    "url": "https://finnhub.io/api/news?id=a54cd660b26755ae10a3b9e934703a3ef0570824d5030660a3f6c937e7b1b963",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763655403,
      "headline": "Inside Our Portfolio: The Investments We Plan To Own For Life",
      "id": 137564184,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2204922269/image_2204922269.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Building a successful portfolio relies on a concentrated, well-researched selection of high-quality compounding engines. Read more on portfolio strategy and allocation.",
      "url": "https://finnhub.io/api/news?id=a54cd660b26755ae10a3b9e934703a3ef0570824d5030660a3f6c937e7b1b963"
    }
  },
  {
    "ts": null,
    "headline": "MRK HIV Regimen Meets Goal in New Study, Gains EU Nod for Keytruda SC",
    "summary": "Merck reports strong new HIV study results showing non-inferiority of DOR/ISL to Gilead's Biktarvy and secures an EU approval for its faster-to-administer SC version of Keytruda.",
    "url": "https://finnhub.io/api/news?id=d116ae1c546f05dfb469d62962543f0f359c28358ff1f36aea02087b15a0451b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763650140,
      "headline": "MRK HIV Regimen Meets Goal in New Study, Gains EU Nod for Keytruda SC",
      "id": 137563007,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck reports strong new HIV study results showing non-inferiority of DOR/ISL to Gilead's Biktarvy and secures an EU approval for its faster-to-administer SC version of Keytruda.",
      "url": "https://finnhub.io/api/news?id=d116ae1c546f05dfb469d62962543f0f359c28358ff1f36aea02087b15a0451b"
    }
  },
  {
    "ts": null,
    "headline": "Merck Is Buying Cidara Therapeutics for $9.2 Billion. Is This the Boost the Lagging Drugmaker Needs?",
    "summary": "The pharmaceutical giant's post-Keytruda plans continue to take shape.",
    "url": "https://finnhub.io/api/news?id=365fd711df82d9a0902c2316a0850af80d83c4312d4b857a6090a7c0227eb2b4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763649900,
      "headline": "Merck Is Buying Cidara Therapeutics for $9.2 Billion. Is This the Boost the Lagging Drugmaker Needs?",
      "id": 137556459,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The pharmaceutical giant's post-Keytruda plans continue to take shape.",
      "url": "https://finnhub.io/api/news?id=365fd711df82d9a0902c2316a0850af80d83c4312d4b857a6090a7c0227eb2b4"
    }
  },
  {
    "ts": null,
    "headline": "Here's Why Merck (MRK) is a Strong Value Stock",
    "summary": "The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.",
    "url": "https://finnhub.io/api/news?id=efd0f27d1aeae7a5e08e37f137945152fc4c2917efeda4f2fa0c1c3bb2a58bba",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763649602,
      "headline": "Here's Why Merck (MRK) is a Strong Value Stock",
      "id": 137563008,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.",
      "url": "https://finnhub.io/api/news?id=efd0f27d1aeae7a5e08e37f137945152fc4c2917efeda4f2fa0c1c3bb2a58bba"
    }
  },
  {
    "ts": null,
    "headline": "Edgewise Therapeutics Appoints Commercial Biotech Executive Christopher Martin to its Board of Directors",
    "summary": "Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced the appointment of biotechnology veteran Christopher Martin to its Board of Directors. Mr. Martin brings proven success across all key commercial functions, including marketing, sales, commercial operations, market access, trade and business development.",
    "url": "https://finnhub.io/api/news?id=1cca4c7ddfd6f17e3846e0a38fd34a022a967e25f00796e1b81a1d6b86c7ae31",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763643600,
      "headline": "Edgewise Therapeutics Appoints Commercial Biotech Executive Christopher Martin to its Board of Directors",
      "id": 137556461,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced the appointment of biotechnology veteran Christopher Martin to its Board of Directors. Mr. Martin brings proven success across all key commercial functions, including marketing, sales, commercial operations, market access, trade and business development.",
      "url": "https://finnhub.io/api/news?id=1cca4c7ddfd6f17e3846e0a38fd34a022a967e25f00796e1b81a1d6b86c7ae31"
    }
  },
  {
    "ts": null,
    "headline": "This Drugmaker Is Too Cheap to Ignore. Why Bristol Is a Buy.",
    "summary": "For Big Pharma, the triumph of developing a new lifesaving blockbuster drug that generates billions in revenue is inevitably followed by the reality that drug patents have an expiration date.  It’s a challenge that  Bristol Myers Squibb  is navigating in real time as it faces a sharp drop in sales of Revlimid, a leading treatment for multiple myeloma that lost patent protection in 2022.  Other flagship products approaching their loss of exclusivity in 2028 include Eliquis, a blood thinner, and the intravenous formulation of the cancer immunotherapy Opdivo.",
    "url": "https://finnhub.io/api/news?id=095930a75826d0aee56911bca29526d07044581e6ef8d98e8f635a494a0c3c96",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763643600,
      "headline": "This Drugmaker Is Too Cheap to Ignore. Why Bristol Is a Buy.",
      "id": 137556460,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "For Big Pharma, the triumph of developing a new lifesaving blockbuster drug that generates billions in revenue is inevitably followed by the reality that drug patents have an expiration date.  It’s a challenge that  Bristol Myers Squibb  is navigating in real time as it faces a sharp drop in sales of Revlimid, a leading treatment for multiple myeloma that lost patent protection in 2022.  Other flagship products approaching their loss of exclusivity in 2028 include Eliquis, a blood thinner, and the intravenous formulation of the cancer immunotherapy Opdivo.",
      "url": "https://finnhub.io/api/news?id=095930a75826d0aee56911bca29526d07044581e6ef8d98e8f635a494a0c3c96"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co., Inc. (MRK) Presents at Jefferies London Healthcare Conference 2025 Transcript",
    "summary": "Merck & Co., Inc. (MRK) Jefferies London Healthcare Conference 2025 November 20, 2025 9:30 AM ESTCompany ParticipantsPeter Dannenbaum - Vice President...",
    "url": "https://finnhub.io/api/news?id=04941583550c50c1072a9b4e48b1dd03daa542af20be60b3abb13ab3885a0b1c",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763640805,
      "headline": "Merck & Co., Inc. (MRK) Presents at Jefferies London Healthcare Conference 2025 Transcript",
      "id": 137558806,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Merck & Co., Inc. (MRK) Jefferies London Healthcare Conference 2025 November 20, 2025 9:30 AM ESTCompany ParticipantsPeter Dannenbaum - Vice President...",
      "url": "https://finnhub.io/api/news?id=04941583550c50c1072a9b4e48b1dd03daa542af20be60b3abb13ab3885a0b1c"
    }
  },
  {
    "ts": null,
    "headline": "Merck Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) successfully complete negotiations for WINREVAIR® (sotatercept)",
    "summary": "Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that it has successfully completed negotiations with the pan‑Canadian Pharmaceutical Alliance (pCPA) for WINREVAIR® (sotatercept). The pCPA negotiates on behalf of the provinces, territories, and federal drug programs serving as a critical step in bringing WINREVAIR® closer to public reimbursement.",
    "url": "https://finnhub.io/api/news?id=8c1845bffcea914f5b0334c94d4dc859a5e21a507e572c0e9c509cfff498c7b5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763640000,
      "headline": "Merck Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) successfully complete negotiations for WINREVAIR® (sotatercept)",
      "id": 137556462,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that it has successfully completed negotiations with the pan‑Canadian Pharmaceutical Alliance (pCPA) for WINREVAIR® (sotatercept). The pCPA negotiates on behalf of the provinces, territories, and federal drug programs serving as a critical step in bringing WINREVAIR® closer to public reimbursement.",
      "url": "https://finnhub.io/api/news?id=8c1845bffcea914f5b0334c94d4dc859a5e21a507e572c0e9c509cfff498c7b5"
    }
  },
  {
    "ts": null,
    "headline": "Cidara Therapeutics Is Up Over 100%. Here's What Investors Need to Know.",
    "summary": "Shares in the biotech company have surged on news of a big pharma takeover.",
    "url": "https://finnhub.io/api/news?id=73b14a8a81494f0f37d9130cfbd3b4989aa85b51f3bbf5aacd3e2eec9027fd98",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763639820,
      "headline": "Cidara Therapeutics Is Up Over 100%. Here's What Investors Need to Know.",
      "id": 137556463,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Shares in the biotech company have surged on news of a big pharma takeover.",
      "url": "https://finnhub.io/api/news?id=73b14a8a81494f0f37d9130cfbd3b4989aa85b51f3bbf5aacd3e2eec9027fd98"
    }
  },
  {
    "ts": null,
    "headline": "$100,000 In The S&P 500's 5 Cheapest Healthcare Stocks, 4% Average Dividend Yield",
    "summary": "Discover 5 undervalued large-cap health care stocks using a proven screening method.",
    "url": "https://finnhub.io/api/news?id=d057abb57ab8f45949785205029293c9073aa0bb6830b40b53701c1728a2537a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763637427,
      "headline": "$100,000 In The S&P 500's 5 Cheapest Healthcare Stocks, 4% Average Dividend Yield",
      "id": 137557117,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1487494602/image_1487494602.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Discover 5 undervalued large-cap health care stocks using a proven screening method.",
      "url": "https://finnhub.io/api/news?id=d057abb57ab8f45949785205029293c9073aa0bb6830b40b53701c1728a2537a"
    }
  },
  {
    "ts": null,
    "headline": "133-year-old big pharma company plans layoffs, files WARN notice",
    "summary": "Layoffs are increasing this year, and they're not limited to any one particular industry. We've previously seen high-profile layoffs from fast-growing technology stalwarts, including Amazon and Microsoft. Now, we've learned that Merck & Co., a 133-year-old drug manufacturer, also ...",
    "url": "https://finnhub.io/api/news?id=0915537edf2f74b6be28b2bf33bc841b3c2a45fed98794c27daeea7a082f1d87",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763613795,
      "headline": "133-year-old big pharma company plans layoffs, files WARN notice",
      "id": 137554002,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Layoffs are increasing this year, and they're not limited to any one particular industry. We've previously seen high-profile layoffs from fast-growing technology stalwarts, including Amazon and Microsoft. Now, we've learned that Merck & Co., a 133-year-old drug manufacturer, also ...",
      "url": "https://finnhub.io/api/news?id=0915537edf2f74b6be28b2bf33bc841b3c2a45fed98794c27daeea7a082f1d87"
    }
  }
]